Literature DB >> 2792174

Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure.

L van Bortel1, R Böhm, J Mooij, P Schiffers, K H Rahn.   

Abstract

The total and free steady-state plasma levels of nifedipine in patients with renal failure have been compared with those in subjects with normal renal function. Studies were done after administration of nifedipine 10 mg t.d.s. p.o. for 5 days, after i.v. infusion of 4.4 mg, and after a single 10 mg oral dose. The systemic clearance of nifedipine after a single i.v.-dose was higher in subjects with renal insufficiency (854 ml/min) than in those with normal renal function (468 ml/min). After the single oral dose the AUC (6100 ng.min.ml-1) and maximum plasma concentration (75.0 ng.ml-1) were lower than in subjects with normal renal function (19300 ng.ml-1; 122 ng.ml-1). The plasma protein binding of nifedipine averaged 95.5% in normal subjects and 94.8% in patients with renal failure. Although free and total steady-state plasma levels of nifedipine tended to be somewhat lower than normal in renal failure, the changes in pharmacokinetics and decreased protein binding of nifedipine did not result in a significantly different steady-state plasma level of the drug. The blood pressure response to a given plasma nifedipine level appeared to be enhanced in renal failure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2792174     DOI: 10.1007/bf00558229

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Influence of volume shift in equilibrium dialysis to estimate plasma protein binding of drugs.

Authors:  J J Lohman; P M Hooymans; M T Verhey; M L Koten; F W Merkus
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

2.  Food and nifedipine pharmacokinetics.

Authors:  V F Challenor; D G Waller; B S Gruchy; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

3.  Hypotensive effect of nifedipine in hypertensive patients with chronic renal failure.

Authors:  E Kusano; Y Asano; K Takeda; Y Matsumoto; A Ebihara; S Hosoda
Journal:  Arzneimittelforschung       Date:  1982

Review 4.  Drug therapy in renal failure.

Authors:  M M Reidenberg; D E Drayer
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

5.  Disturbances of peripheral and autonomic nervous system in chronic renal failure: effects of hemodialysis and transplantation.

Authors:  E Heidbreder; K Schafferhans; A Heidland
Journal:  Clin Nephrol       Date:  1985-05       Impact factor: 0.975

6.  Effect of food on nifedipine pharmacokinetics.

Authors:  D P Reitberg; S J Love; G T Quercia; M A Zinny
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

7.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

8.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

Authors:  C H Kleinbloesem; P van Brummelen; M Danhof; H Faber; J Urquhart; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

9.  Pharmacokinetics and metabolism of nifedipine.

Authors:  K D Raemsch; J Sommer
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

10.  Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients.

Authors:  C H Kleinbloesem; P van Brummelen; H Faber; D D Breimer
Journal:  J Cardiovasc Pharmacol       Date:  1987-02       Impact factor: 3.105

View more
  10 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 3.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 4.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

5.  Human lymphatic vessel contractile activity is inhibited in vitro but not in vivo by the calcium channel blocker nifedipine.

Authors:  Niklas Telinius; Sheyanth Mohanakumar; Jens Majgaard; Sukhan Kim; Hans Pilegaard; Einar Pahle; Jørn Nielsen; Marc de Leval; Christian Aalkjaer; Vibeke Hjortdal; Donna Briggs Boedtkjer
Journal:  J Physiol       Date:  2014-08-28       Impact factor: 5.182

6.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 8.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

9.  Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment.

Authors:  R Schneider; D Stolero; L Griffel; R Kobelt; E Brendel; A Iaina
Journal:  Drugs       Date:  1994       Impact factor: 9.546

10.  Cardiac Arrhythmias and Antiarrhythmic Drugs: An Autophagic Perspective.

Authors:  Joanne J A van Bavel; Marc A Vos; Marcel A G van der Heyden
Journal:  Front Physiol       Date:  2018-02-23       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.